公司資料
Ensysce Biosciences 股價、新聞與催化劑
- 股票代碼:
- ENSC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.38 USD (-5.83%)
收盤價
最後更新: 2026年8月17日
3.84M USD
市值
股價為何變動
As of Aug 17, 2026, ENSC closed down 5.83% at $0.3766. No new same-company headline was identified in the current news window.
公司概覽
Complex-Pain Therapeutics
Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain. The company expanded its strategy through the acquisition of Cy Biopharma.
CY200
CY200 is an orphan-designated neuroplastogenic candidate for complex regional pain syndrome type 1. It is designed to address the underlying neurobiology of the disorder rather than only managing symptoms.
Protected Opioid Platform
Ensysce's Trypsin-Activated Abuse Protection technology keeps opioid prodrugs inactive until they reach the small intestine. PF614 applies this approach to an extended-release oxycodone product.
Overdose-Protection Program
PF614-MPAR combines abuse protection with Multi-Pill Abuse Resistance technology intended to limit oral overdose. The program has received FDA Breakthrough Therapy designation.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。